- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
Fms-like tyrosine kinase 3 (FLT3), also known as CD135, is a class III receptor tyrosine kinase involved in hematopoietic progenitor regulation, immune-associated signaling pathways, and cytokine-responsive cellular development mechanisms. CD135 Antibody / Hematopoietic Progenitor Marker is suitable for investigations involving hematopoietic differentiation, lymphoid tissue biology, progenitor cell-associated signaling, and immune regulatory pathways. FLT3 signaling contributes to maintenance of progenitor cell populations and regulation of developmental signaling environments associated with hematopoietic tissue organization.
CD135 antibody, also referred to as FLT3 antibody, Fms-like tyrosine kinase 3 antibody, FLK2 antibody, and Hematopoietic progenitor receptor antibody in the literature, recognizes a transmembrane receptor associated with cytokine-responsive hematopoietic regulation. FLT3 is widely studied in immune-associated signaling pathways and progenitor cell biology because activation of FLT3-associated signaling cascades contributes to cellular proliferation, survival, and lineage-associated differentiation programs. Through downstream PI3K-AKT, MAPK, and STAT-associated signaling pathways, FLT3 participates in regulation of hematopoietic developmental responses.
FLT3 signaling additionally plays an important role in leukemia-associated biology and hematologic malignancy research environments. However, CD135 is particularly recognized as a hematopoietic progenitor-associated surface receptor involved in developmental and immune regulatory pathways. Expression of FLT3/CD135 has been associated with progenitor cell populations and selected immune-associated cellular environments within hematopoietic tissues.
Receptor tyrosine kinases such as FLT3 influence multiple interconnected signaling systems controlling proliferation, differentiation, cytokine responsiveness, and developmental cellular regulation. Because FLT3 signaling contributes to broader hematopoietic and immune-associated regulatory pathways, CD135 remains relevant for investigations involving progenitor cell biology, immune signaling regulation, and hematopoietic tissue-associated developmental mechanisms.
Immunohistochemistry analysis supports detection of endogenous CD135 expression in spleen tissue, consistent with the expected distribution profile of this hematopoietic progenitor-associated receptor tyrosine kinase. Western blot analysis additionally supports detection of FLT3-associated protein expression in cultured human cells. The combined validation profile supports use of this rabbit polyclonal antibody for investigations involving hematopoietic progenitor signaling, immune-associated receptor tyrosine kinase biology, and cytokine-responsive cellular regulation pathways.
An antibody targeting CD135 can therefore support studies involving hematopoietic progenitor-associated signaling, immune regulatory pathways, cytokine-responsive cellular development, receptor tyrosine kinase biology, and hematologic signaling-associated cellular regulation.
For broader receptor tyrosine kinase and leukemia-associated signaling research applications, explore our FLT3 Antibody / Receptor Tyrosine Kinase Marker page.
Optimal dilution of the CD135 Antibody / Hematopoietic Progenitor Marker should be determined by the researcher.
Recombinant human protein (amino acids A66-S993) was used as the immunogen for the CD135 antibody.
After reconstitution, the CD135 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
CD135 antibody, FLT3 antibody, Fms-like tyrosine kinase 3 antibody, FLK2 antibody, Hematopoietic progenitor receptor antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.